Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients without the systemic side effects associated with current treatments [4]. Stock Option Grant - On May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to a new employee under its 2022 Inducement Stock Incentive Plan [1]. - The exercise price for the stock options is set at $0.755 per share, which matches the closing price of the company's common stock on the grant date [2]. - The stock options have a ten-year term, with 25% of the shares vesting on the first anniversary of employment and the remaining 75% vesting in 36 equal monthly installments, contingent on continued service with the company [2][3]. Compliance and Inducement - The stock options are granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the individual entering employment with the company [3].